Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, et al.: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate. 1995, 26: 164–8. 10.1002/pros.2990260308
Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, et al.: Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology. 1998, 51: 89–97. 10.1016/S0090-4295(98)00082-X
Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urology. 1998, 160: 2396–401. 10.1016/S0022-5347(01)62198-0
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998, 83: 2259–69. 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T
Sweat SD, Pacelli A, Murphy GP, Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998, 52: 637–40. 10.1016/S0090-4295(98)00278-7
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997, 3: 81–5.
Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, et al.: Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009, 40: 1754–61. 10.1016/j.humpath.2009.06.003
Haffner MC, Laimer J, Chaux A, Schafer G, Obrist P, Brunner A, et al.: High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012, 25: 1079–85. 10.1038/modpathol.2012.66
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al.: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997, 57: 3629–34.
Chang SS, Gaudin PB, Reuter VE, O’Keefe DS, Bacich DJ, Heston WD: Prostate-specific membrane antigen: much more than a prostate cancer marker. Mol Urol. 1999, 3: 313–20.
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999, 5: 2674–81.
Baccala A, Sercia L, Li J, Heston W, Zhou M: Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007, 70: 385–90. 10.1016/j.urology.2007.03.025
Ross JS, Schenkein D, Webb I, Gray G, Deeds J, Meyer R, et al.: Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol, New Orleans, LA; 2004.
Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nuc Med. 2003, 44: 610–7.
Bander NH, Nanus D, Bremer S: Phase 1 clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer [abstract 1872]. Proc Am Soc Clin Oncol 2000, 19: 477a.
Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003, 30: 667–76. 10.1016/S0093-7754(03)00358-0
Vallabhajosula S, Kuji I, Kostakoglu L, Smith-Jones PM, Zoe H, Bander NH, et al.: Radiolabeled humanized monoclonal antibodies to PSMA: phase I dose escalation studies with In-111-DOTA-hu-J591. J Nucl Med. 2001, 42: 122P-3.
Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O’Donoghue JA, Nacca A, et al.: Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007,13(9):2707–13. 10.1158/1078-0432.CCR-06-2935
Morris MJ, Divgi C, Kelly WK, Slovin S, Solit D, Shaffer D, et al.: Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors. Proc Am Assn Cancer Res Ann Mtg. 2003, 44: 803.
Pandit-Taskar N, O’Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al.: Antibody mass escalation study in patients with castration-resistant prostate cancer using (111)In-J591: lesion detectability and dosimetric projections for (90)Y radioimmunotherapy. J Nucl Med 2008,49(7):1066–74. 10.2967/jnumed.107.049502
Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al.: Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific-membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005, 11: 7454–61. 10.1158/1078-0432.CCR-05-0826
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al.: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007,25(5):540–7. 10.1200/JCO.2006.07.8097
Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al.: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998, 47: 484–92. 10.1016/S0026-0495(98)90064-6
Gonen M, Panageas KS, Larson SM: Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001, 221: 763–7. 10.1148/radiol.2212010280